Healthsonix Inc. DL-,001

seit meinem letzten posting gab es 2 News und momentan sieht es ganz gut aus (in USA).  

Was für zwei News meinst Du denn?
Gruss
RPM  

http://biz.yahoo.com/iw/070425/0244059.html

 

http://biz.yahoo.com/iw/070503/0247654.html

 

 

 

Wie interpretierst Du persönlich die News?
1 Bad 1 Good
oder
2 * Good  

es wird noch viel besser kommen, aber bisher waren alle gemeldeten Fortschritte nicht gerade "Bad" :-).  

Bin deiner Meinung! Aber mit der Advertising Geschichte kann ich mich nicht wirklich anfreunden.
Klingt bei der "angespannten" Finanzlage von Healthsonix ein wenig nach "verwässern".
Gibt es Aussagen zur Finanzierung der Werbemaßnahme??
 

gab es keine mir bekannten konkreten Zahlen, aber auch keine Verwässerung. Es werden ja bereits Umsätze erzielt (vor allem mit der AquaSonix Therapie) und die Firma ist wohl auch kreditwürdig (siehe zB. abgeschlossene Verträge über das enSonix-Gerät in Höhe von ca. 17 Mio USD), denn es wird auch ein Firmengebäude errichtet.

 

Ist aber ein weiteres Risko.
Es gibt immer noch genug, die bei Healthsonix auf einen Short setzen und das ist in meinem Augen Wasser auf die Mühlen, oder wem das besser gefällt Öl ins Feuer.
Aber wie gesagt, ich bin und bleibe positioniert und sitze das aus bis mein(e) Kursziel(e) erreicht sind.
Notfalls überziehe ich auch mein angesetztes Budget, denn wie schon gesagt, die Firma ist kurz oder lang eine Gelddruckmachine ;o)  

http://biz.yahoo.com/iw/070509/0250433.html

aber in D kriegt es kaum einer mit - noch nicht *g*.

 

Das ist in meinen Augen jetzt wieder einmal eine 100% Good News.
Mal schauen wie Pink Sheet darauf reagiert! ;o)
Leider habe ich nur noch 6% Cash im Depot. :(
 

von zB. 1 Mio sind auch 60K und das sind momentan viele Shares, besonders wenn man die in D kaufen will, das kann mühselig werden oder den Kurs gewaltig beflügeln.

Alles relativ :-)....  

Da hast Du absolut Recht.
Aber da gibt es gewisse Beschränkungen gegenüber Aktiengesetz und Verträgen.
Ausserdem gibt es auch noch andere Einstiegschancen.
Mehr als 10% in sogenannte Hotsocks sind leider ebenfalls nicht drin.
Ausserdem sieht es immer mehr danach aus, das HS seine guten Aussichten bestätigen muss, damit wieder richtig Bewegung in die Aktie kommt.
Ansonsten pendeln wir ständig um die 0,20 bis 0,30 E-Cent und das ist leider der Spreed zwischen Geld und Brief in Deutschland.  

Entweder hab ich irgendeine Bad News nicht mitbekommen oder da gibt es Shares im Sonderangebot.
Oder jemand will um Teufelkommraus Verluste ausweisen.
Dann hätte er aber doch zu 0,21 verkauft.

Warum hab ich gerade jetzt 0% Cash!
 

Source: Market Wire (May 15, 2007 - 9:39 AM EDT)

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it has achieved successful results in the treatment of patients with Dupuytren's Contracture using its sound pulse technology.

Dupuytren's Contracture, a disease of the palmar fascia, results in the thickening and shortening of fibrous bands in the hands and fingers. The incidence of Dupuytren's contracture is highest in Caucasians, historically those of Celtic descent. It most often affects the ring or little finger, sometimes both, and often in both hands. Although the exact cause is unknown it is genetic in nature, meaning it runs in families. This condition is seven times more common in men than women. The disorder may occur suddenly but more commonly progresses slowly over a period of years. The disease usually doesn't cause symptoms until after the age of 40.

Without treatment, such as surgical intervention, the Contracture can become so severe that the patient cannot straighten his/her finger, and eventually they may not be able to use their hand effectively.

"We were quite pleasantly surprised by the fact that our sound pulses were able to relieve some of the stiffness and in some cases even restore mobility," said Dr. David Venturi, Medical Director of HealthSonix. "More clinical work will commence shortly to further study and expand on treatment outcomes," added Dr. Venturi.

HealthSonix sound pulse technology has now been made available for home use in the state of the art, self-administered enSonix@home medical device. The enSonix@home device will be available online May 22, 2007, when the company launches its new online store: www.MyArthritisStore.com

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact


 

Also ich habe keine Infos mehr aus der USA bekommen ob heute der neue Short iniziert werden soll.
Anscheinend haben welche aus dem Club die Meldungen von mir über Google gefischt und jetzt ist Informationssperre für mich.
Weiß jemand etwas über Shortattacken für heute oder morgen?  

-25% in den USA nach -10% gestern.
Sehen wir alte Tiefs?  

About Marketwire
Workflow Solutions
Resource Center
News Room
Contact Us
Home
Version Française
Other News    Advanced Search    All Recent News    Email a Friend    Print  

SOURCE: HealthSonix, Inc.
 
Jun 19, 2007 08:48 ET
HealthSonix to Launch Combination Therapy Program With a Major Pharmaceutical Company for Patients with Advanced Rheumatoid Arthritis
Highlighted Links


AquaSonix
IRVINE, CA--(Marketwire - June 19, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today that it will commence joint marketing programs with its proprietary AquaSonix Therapy and a biologic therapy medication used in adults to reduce the signs and symptoms of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

"From the beginning, we have stressed that combination therapy is the future for treating the pain associated with arthritis, and we are indeed pleased that a major New York Stock Exchange listed pharmaceutical company is partnering with us in an effort to develop the 'treatment of choice' for patients suffering with rheumatoid Arthritis," said Dieter D. Doederlein, Vice President Corporate Development.

The joint marketing programs will commence in September of 2007, with immediate revenue stream to the Company. "This gives us the time to develop new promotional materials and to cross train the sales forces on the benefits of combination therapies," added Mr. Doederlein.

The biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.

It is widely accepted that one of the most effective treatments for the long-term management of the symptoms of immunological disorders is physical exercise. However, it has been suggested that weight-bearing exercises -- even exercise considered 'normal' -- can aggravate pain and further promote degeneration in patients with abnormal joints. This is particularly true if the joints have incongruous articular surfaces, poor alignment, ligamentous instability, or altered muscle or joint innervation, as is often the case in patients with immunological conditions.

Unfortunately this diminishes the options for the patient with joint degeneration, which often results in a discontinuation of exercise altogether. Ironically, the ensuing immobility and lack of dynamic joint loading further damage joint surfaces leading to a spiral of immobility and degeneration.

The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.

"This new partnership represents a significant development in the fight against arthritis because the guidelines published by the American College of Rheumatology [ACR] for both rheumatoid and osteo arthritis stress that the combination of medications and non pharmacological therapies is the optimal way to treat the patients," said Doederlein.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact       Click here to see all recent news

Privacy Statement | Terms of Service | Sitemap |© 2007 Marketwire, Incorporated. All rights reserved.
1-800-774-9473 (US)  |  1-888-299-0338 (Canada)  |  +44-20-7562-6550 (UK)

(C) 2007 Marketwire Incorporated

 

HealthSonix Inc.: Update: HealthSonix Registers AquaSonix Medical Device With the FDA
June 22, 2006
IRVINE, CA (MARKET WIRE) HealthSonix Inc. ("HealthSonix" or the "Company") (PINKSHEETS: HSXI) www.HealthSonix.com, is pleased to announce that it has registered the AquaSonix medical device with the United States Food and Drug Administration (FDA). Indications are for pain reduction and muscle relaxation. The device was designated as class 1, the safest classification for medical devices.

Quelle LincOn.com
http://news.lincon.com/news.php/Business/11/2006-06-22
Gruß
RPM  

Approximately 1:30 EST – Tuesday, May 22, 2007

New Green Baron Focus Stock Pick;

Now Upgraded to Fully Profiled Pick



HealthSonix, Inc.

(PK: HSXI - .35 per share)



Insight. Innovation. Integrity

www.HealthSonix.com

Common Shares Outstanding / 51.9 million

Current Market Cap / $18.16 million

52-Week High / $1.34 per share  

52-Week Low / .075 per share

Average Price / .2030 (50-day)  .4142 (200-day)

Average Volume / 512,600 (50-day)  364,000 (200-day)

HealthSonix Ready to Widely Distribute FDA Registered Drug Free Pain Relief Products for Arthritis and other Musculoskeletal Conditions

Infomercials, MyArthritisStore.com, and Co-Marketing Agreements Expected to Create Huge Sales Growth

The Green Baron Report has been closely watching developments at HealthSonix ever since we first interviewed the company back in February.  The potential for this Company is simply jaw dropping, and quite honesty, we had trouble at first believing that this company really had such effective products.  Simply put, the market for its pain relieving products is many billions of dollars each year, and even a small percentage of this market would be huge.  Under much further investigation, we not only believe the claims from the Company, but we think this is just the start of a much bigger move up in the stock due to greatly improving fundamental and technical reasons.

The Green Baron Report is proud to announce that HealthSonix, Inc. (PK: HSXI) is officially our 62nd fully profiled stock and will be added to our storied list of previously profiled stocks on our home page.  Results compiled from the most recent trade possible prior to dissemination of this report to the subsequent high will be monitored at www.thegreenbaron.com.   Although we have very aggressive short and long term expectations for this stock, we still suggest our members try to accumulate at or as near the profile price as possible.  

NOTE: HealthSonix, Inc. was originally introduced by The Green Baron Report through a webcast interview with its CEO in February, 2007.  Although HSXI has performed strongly over the past month or so, we believe that recent consolidation is over in the mid .30 per share range, and the stock is now ready for its next move higher.  Over the past five weeks, we successfully alerted our members within days of the two huge percentage moves up in HSXI stock. We have reason to believe once again, a third time, that HSXI will rally over the near term to much higher levels, and a move well above $1.00 per share could occur over the next 90 days.  

It has become increasingly important to manage pain associated with arthritis and other musculoskeletal conditions without the use of drugs.  Due to adverse side affects, addiction concerns, and other negative reactions to prescription pain killers, there is a growing need for “non-pharmacologic” treatments, or at least a combination of non-pharmacologic and pharmacologic modalities of treatment.

HealthSonix offers a variety of proven non-pharmacologic therapies with its proprietary sound pressure wave treatments, such as AquaSonix Therapy – a therapeutic water program that combines the Company’s sound pulse technology with the Arthritis Foundation’s low impact exercises in warm water therapy pools.  The proprietary sound pulse technology is believed to work by stimulating mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control of pain); by creating an exercise effect in the muscles, which encourages the production and release of endorphins, the body’s natural pain killers.

Over the past two months, HealthSonix has released several announcements that identify the Company’s coming high growth phase, and its establishment as a new force in massive markets.  More specifically, we are impressed by a press release issued on Wednesday, April 11, 2007 where HealthSonix announced it will conduct joint clinical studies with major drug manufacturers.  We believe the big pharmaceutical companies are beginning to take notice, and it is only a matter of time before stronger collaborations are forged.

Among other releases, HealthSonix has recently launched a new pain relieving cream under the ZingiberRx brand name priced at about $20, is set to launch MyArthritisStore.com, and has announced positive reviews and studies for its products.  See Recent Key Press Releases below for more information.  Fundamentally, The Green Baron Report believes HealthSonix is at the best point in the Company’s history, and we expect the Company to surprise us with more fantastic new developments in the near future.

HSXI appears to be under accumulation by some very smart buyers.  The stock has held steady at about .34 to .36 per share for about two weeks now.  HSXI has hit .50 per share and .45 per share on its last two moves up on heavy volume.  The next break over .45 per share should take the stock on another big move up.  The recent 10 day average volume is over 700,000 shares traded.  Liquidity is fantastic and the spread is typically a penny or less.

We note that HSXI traded between about .60 per share and $1.20 per share from June to September of 2006.  Year-end tax selling and a few impatient shareholders took HSXI down late last year.  We believe HealthSonix is aiming to gain a listing on the American Stock Exchange this year, and discussions with those close to HealthSonix believe the stock will be above $1 per share within weeks.

http://www.thegreenbaron.com/Stock%20Picks/05-22-07%20Stock%20Pick.htm
 

SOURCE: HealthSonix, Inc.
   
Jul 16, 2007 12:31 ET
HealthSonix Completes Infomercial for the enSonix@home Medical Device
Highlighted Links


AquaSonix
IRVINE, CA--(Marketwire - July 16, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today it has finished filming the infomercial at MG Studios in Orlando, Florida over the course of the last several weeks. MG Studios is a state-of-the-art audio and video facility staffed with industry veterans formally with Disney and Universal Studios.

The infomercial focuses on the enSonix@home, self-administered, medical device that uses sound pressure waves to relieve pain and relax the muscles. The device is particularly effective in treating the pain of arthritis, fibromyalgia, low back pain and soft tissue injuries. The product is presented in a clinical setting by medical professionals along with testimonials from patients that have used the device in the comfort of their homes.

CEO and President of HealthSonix, Michael Ivezic, stated, "This is a high quality production using the finest high-definition equipment. The product is presented with the look and feel of a major quality broadcast. The personnel at MG studios are consummate professionals and were a pleasure to work with on this project. We are confident that this commercial will present our device commensurately to the buying public. The infomercial will spearhead of our product launch and we anticipate that this is the first step to establishing the device and brand awareness to the everyday consumer in a big way."

The infomercial is slated to be aired in the fall of this year. It is expected that sales will parallel or exceed the huge success of other pain relief devices promoted by infomercials due to the fact that HealthSonix's product is FDA cleared with substantial clinical evidence supporting the claims.

About MG Studios: "IDEAS START HERE" MG Studios is a state-of-the-art, full service, fully digital production and multimedia company based in Orlando Florida. MG specializes in film, video and post production operating in a 6,000 sq. ft. facility. The studio includes a green screen, edit suites, graphics suites, 3D animation suites and a recording studio. Combining leading edge technology and experienced professional writers, directors, editors, animators and composers, MG Studios creatively meets the high demands of any project. See www.mgstudios.com

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent-pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact       Click here to see all recent news from this company  

Und was soll uns das jetzt sagen?Kaufen ,verkaufen ,heulen oder lachen?
Habe kleine Posi's davon im Depot zu liegen und das schon ein paar Monate.Fahre derzeit günstig im Plusbereich.
jaaa ,abstossen oder halten das ist immer die alles entscheidene Frage.  

laufen lassen ,da ist mehr drinn.:-)))  

 

verschiedensten Papieren im Depot zu liegen.Bei mir ist das genauso.Da sollte man auch regelmässig reinschauen ,so oft es geht.
Healthonix läuft gut:-)  

mit dem meditienischen Krempel.Mein Ding ,hat Zukunft.